Version 1.0 · 5 November 2026 · Draft for legal and operational review
Acceptable Use Policy
This policy supplements the AQIENTRA Terms and Conditions. The final published version must be reviewed against the Platform's actual features and applicable Nigerian law.
Users must use AQIENTRA lawfully, safely, respectfully and only within the permissions assigned to their account and Organisation.
1. Account and access security
- Use only your own account; never share passwords or verification links.
- Use multi-factor authentication where AQIENTRA makes it available.
- Do not attempt to access another user's account, Organisation, branch or records.
- Report suspected compromise, unauthorised access or lost devices promptly.
2. Prohibited conduct
- Fraud, impersonation, credential falsification or misleading professional claims.
- Unlawful sale, supply, manufacture, prescription or dispensing of medicines or regulated products.
- Malware, phishing, denial-of-service activity, vulnerability exploitation or interference with Platform availability.
- Scraping, bulk extraction, resale or unauthorised disclosure of Platform data.
- Harassment, discrimination, threats, unlawful content or infringement of third-party rights.
- Using the Platform to bypass regulatory checks, subscription restrictions or moderation.
3. Healthcare and regulated information
Only authorised persons may conduct regulated activities. Users must not upload patient information to public areas or general support channels. Organisations must configure least-privilege access and comply with confidentiality, recordkeeping, professional and data-protection obligations.
4. Enforcement
AQIENTRA may investigate reported misuse and may remove content, restrict features, suspend accounts or refer matters to competent authorities where required. Decisions will be proportionate to the risk and subject to applicable law. Where practicable, affected users will be notified and given an appropriate review channel.
5. Reporting
Report abuse or security concerns through AQIENTRA's designated support channel. Do not publicly disclose suspected vulnerabilities before giving AQIENTRA a reasonable opportunity to investigate.